InspireMD

Yahoo Finance • 9 days ago

InspireMD Q4 Revenue Up, Guides For 65% Growth In 2026, Stock Rise

(RTTNews) - InspireMD, Inc. (NSPR), the developer of the CGuard Prime carotid stent system, reported fourth-quarter and full-year 2025 financial results that showed solid revenue growth driven by expanding U.S. adoption and steady internat... Full story

Yahoo Finance • 10 days ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Macy's (M [https://seekingalpha.com/symbol/M]) * General Mills (GIS [https://seekingalpha.com... Full story

Yahoo Finance • 12 days ago

Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag

Information technology, industrials and utilities are set to feature prominently in this week’s earnings calendar, with 249 companies scheduled to report. This week’s quant rankings highlight strong momentum among technology and industria... Full story

Yahoo Finance • 4 months ago

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of... Full story

Yahoo Finance • 4 months ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of... Full story

Yahoo Finance • 4 months ago

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion at the upcoming Pipe... Full story

Yahoo Finance • 5 months ago

InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas,... Full story

Yahoo Finance • 8 months ago

InspireMD Reports Second Quarter 2025 Financial Results

--- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of str... Full story

Yahoo Finance • 8 months ago

RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the... Full story

Yahoo Finance • 8 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen... Full story

Yahoo Finance • 8 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial resul... Full story

Yahoo Finance • 9 months ago

InspireMD launches CGuard Prime carotid stent in US after FDA approval

MIAMI - InspireMD, Inc. (NASDAQ:NSPR) announced Wednesday the commercial launch of its CGuard Prime carotid stent system in the United States following FDA premarket application approval. According to InvestingPro data, the company maintai... Full story

Yahoo Finance • 9 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) ha... Full story

Yahoo Finance • 9 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medic... Full story

Yahoo Finance • 10 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael... Full story

Yahoo Finance • last year

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, and NAMSA, a world-leading MedTech Co... Full story

Yahoo Finance • 2 years ago

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

TEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the company has entered into... Full story

Yahoo Finance • 2 years ago

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular... Full story

Yahoo Finance • 2 years ago

InspireMD to Participate in Upcoming November Investor Conferences

TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today an... Full story

Yahoo Finance • 2 years ago

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

TEL AVIV, Israel and MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today presented 30-day results from the C-GUARDIAN... Full story